	US 11,987,616 B2
	Antigen binding molecules targeting SARS-CoV-2
Gevorg Grigoryan, Arlington, MA (US); and John Ingraham, Cambridge, MA (US)
Assigned to Flagship Pioneering Innovations VI, LLC, Cambridge, MA (US)
Filed by Flagship Pioneering Innovations VI, LLC, Cambridge, MA (US)
Filed on Feb. 15, 2023, as Appl. No. 18/169,464.
Application 18/169,464 is a continuation of application No. PCT/US2021/047757, filed on Aug. 26, 2021.
Claims priority of provisional application 63/070,707, filed on Aug. 26, 2020.
Prior Publication US 2023/0287089 A1, Sep. 14, 2023
Int. Cl. C07K 16/10 (2006.01); A61P 31/14 (2006.01); A61K 39/00 (2006.01)

CPC C07K 16/10 (2013.01) [A61P 31/14 (2018.01); A61K 39/00 (2013.01); C07K 2317/569 (2013.01)]

27 Claims

1. A polypeptide that specifically binds a severe acute respiratory syndrome coronavirus 2 Spike glycoprotein (SARS-CoV-2-Spike), comprising an immunoglobulin heavy chain variable domain (V_H) amino acid sequence comprising a heavy chain complementarity determining region 1 (HCDR1), a heavy chain complementarity determining region 2 (HCDR2) and a heavy chain complementarity determining region 3 (HCDR3) that are identical to the HCDR1, HCDR2 and HCDR3, respectively, of the amino acid sequence of SEQ ID NO: 4.